Literature DB >> 26264207

The Ins and Outs of Nanoparticle Technology in Neurodegenerative Diseases and Cancer.

Cornelia M Wilson1, Amandine Magnaudeix, Thomas Naves, François Vincent, Fabrice Lalloue, Marie-Odile Jauberteau.   

Abstract

As we enter the twenty-first century, several therapies based on using nanoparticles (NPs) ranging in size 1 - 1000 nm have been successfully brought to the clinic to treat cancer, pain and infectious diseases. These therapies bring together the ability of NPs to target the delivery of drugs more precisely, to improve solubility, to prevent degradation, to improve their therapeutic index and to reduce the immune response. NPs come in all shapes and sizes, designed specifically for biomedical applications such as solid lipid polymers, liposomes, dendrimers, nanogels, and quantum dots. These NPs offer many attractive characteristics such as biological stability and biocompatibility, thus incorporating different biological or drug molecules. Among the major therapeutic challenges from neurological diseases through to cancer is the development of nanomaterials that are able to be effective against the disease. In the case of neurodegeneration, one of the most difficult areas to penetrate for drug discovery in the body is the central nervous system, protected by the blood-brain-barrier. Whilst in the case of cancer, the biggest problem is how to specifically target a tumor with sufficient drug without causing side effects or inducing resistance. A new generation of intelligent NPs are emerging for the treatment of human disease such as neurological disorders and cancer. The use of natural alternative therapy is an encouraging idea in drug discovery. To this end as we gain more knowledge into the biological function of exosomes, this will allow us to harness their potential as natural NPs in future therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26264207     DOI: 10.2174/1389200216666150812121902

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  3 in total

Review 1.  Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases.

Authors:  Palanivel Ganesan; Prakash Ramalingam; Govindarajan Karthivashan; Young Tag Ko; Dong-Kug Choi
Journal:  Int J Nanomedicine       Date:  2018-03-15

2.  Anti-α4β7 monoclonal antibody-conjugated nanoparticles block integrin α4β7 on intravaginal T cells in rhesus macaques.

Authors:  Sidi Yang; Geraldine Arrode-Bruses; Ines Frank; Brooke Grasperge; James Blanchard; Agegnehu Gettie; Elena Martinelli; Emmanuel A Ho
Journal:  Sci Adv       Date:  2020-08-21       Impact factor: 14.136

Review 3.  The Delivery Challenge in Neurodegenerative Disorders: The Nanoparticles Role in Alzheimer's Disease Therapeutics and Diagnostics.

Authors:  Cristina de la Torre; Valentín Ceña
Journal:  Pharmaceutics       Date:  2018-10-17       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.